Alpha Tau Medical (NASDAQ:DRTS) Trading Up 1.6%

Alpha Tau Medical Ltd. (NASDAQ:DRTS) shares were up 1.6% during mid-day trading on Monday . The company traded as high as $2.27 and last traded at $2.20. Approximately 18,408 shares were traded during trading, a decline of 45% from the average daily volume of 33,180 shares. The stock had previously closed at $2.16.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Alpha Tau Medical in a research report on Wednesday, May 22nd.

Alpha Tau Medical Trading Up 1.6 %

The company has a debt-to-equity ratio of 0.07, a current ratio of 11.60 and a quick ratio of 11.60. The company has a market cap of $152.93 million, a price-to-earnings ratio of -5.35 and a beta of 0.75. The business’s 50-day simple moving average is $2.50 and its 200-day simple moving average is $2.84.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings results on Monday, May 20th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. Research analysts predict that Alpha Tau Medical Ltd. will post -0.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Levin Capital Strategies L.P. grew its holdings in shares of Alpha Tau Medical by 2.6% during the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after buying an additional 8,641 shares in the last quarter. Private Advisor Group LLC purchased a new stake in shares of Alpha Tau Medical during the fourth quarter worth about $176,000. Satovsky Asset Management LLC purchased a new stake in Alpha Tau Medical in the fourth quarter valued at approximately $176,000. Telemus Capital LLC purchased a new stake in Alpha Tau Medical in the fourth quarter valued at approximately $89,000. Finally, USAdvisors Wealth Management LLC purchased a new stake in Alpha Tau Medical in the first quarter valued at approximately $30,000. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.